Excelitas Moves to Further Expand and Broaden its Industrial Technology Portfolio with a Highly Complementary Set of Photonic Solutions across the Lighting Spectrum
Excelitas TechnologiesÒ Corp., a leading industrial and medical technology manufacturer focused on delivering innovative, market-driven photonic solutions, announced that it has signed a definitive agreement with Heraeus Group (Hanau, Germany) to acquire the Heraeus Noblelight business with approximately 850 employees, including operations in Germany, United Kingdom, United States, China and Japan, along with several key application centers.
Heraeus Noblelight is an operative company within Heraeus Group, a broadly diversified and globally leading family-owned technology group. Heraeus Noblelight specializes in the development and manufacture of specialty light sources and solutions, from ultraviolet to infrared, used within analytical instrumentation, industrial curing, water treatment, electronics manufacturing, medical and cosmetic therapy, battery production and many others.
"We see tremendous potential in the union of Heraeus Noblelight’s technology portfolio with our own extensive offering in plasma and LED products. Leveraging our combined investments and expanded offering will drive growth and present innovative integrated solutions to our highly complementary customer and product mix across a variety of unique markets,” said Michael Ersoni, Excelitas Technologies EVP Commercial Business.
The acquisition of Heraeus Noblelight will represent the latest in a series of strategic acquisitions by Excelitas Technologies since its establishment in 2010.
"As a leading player in the specialty light market, Heraeus Noblelight has a strong footprint in the areas of market access, problem-solving expertise, and technological bandwidth. We are convinced, that this agreement will further boost Heraeus Noblelight’s stable growth path of the last years,” said Jan Rinnert, CEO and Chairman of the Board of Managing Directors of Heraeus Group.
The agreement has been approved by both companies. Terms are not being disclosed and the transaction is expected to close before the end of 2023 (subject to obtaining regulatory approvals).